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BACKGROUND
Uterine fibroids are hormone-responsive neoplasms that are associated with heavy 
menstrual bleeding. Elagolix, an oral gonadotropin-releasing hormone antagonist re-
sulting in rapid, reversible suppression of ovarian sex hormones, may reduce fibroid-
associated bleeding.
METHODS
We conducted two identical, double-blind, randomized, placebo-controlled, 6-month 
phase 3 trials (Elaris Uterine Fibroids 1 and 2 [UF-1 and UF-2]) to evaluate the effi-
cacy and safety of elagolix at a dose of 300 mg twice daily with hormonal “add-back” 
therapy (to replace reduced levels of endogenous hormones; in this case, estradiol, 1 mg, 
and norethindrone acetate, 0.5 mg, once daily) in women with fibroid-associated bleed-
ing. An elagolix-alone group was included to assess the impact of add-back therapy on 
the hypoestrogenic effects of elagolix. The primary end point was menstrual blood loss 
of less than 80 ml during the final month of treatment and at least a 50% reduction 
in menstrual blood loss from baseline to the final month; missing data were imputed 
with the use of multiple imputation.
RESULTS
A total of 412 women in UF-1 and 378 women in UF-2 underwent randomization, re-
ceived elagolix or placebo, and were included in the analyses. Criteria for the primary 
end point were met in 68.5% of 206 women in UF-1 and in 76.5% of 189 women in UF-2 
who received elagolix plus add-back therapy, as compared with 8.7% of 102 women and 
10% of 94 women, respectively, who received placebo (P<0.001 for both trials). Among 
the women who received elagolix alone, the primary end point was met in 84.1% of 
104 women in UF-1 and in 77% of 95 women in UF-2. Hot flushes (in both trials) and 
metrorrhagia (in UF-1) occurred significantly more commonly with elagolix plus add-
back therapy than with placebo. Hypoestrogenic effects of elagolix, especially de-
creases in bone mineral density, were attenuated with add-back therapy.
CONCLUSIONS
Elagolix with add-back therapy was effective in reducing heavy menstrual bleeding in 
women with uterine fibroids. (Funded by AbbVie; Elaris UF-1 and Elaris UF-2 Clinical-
Trials.gov numbers, NCT02654054 and NCT02691494.)
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Uterine fibroids (leiomyomas), com-mon noncancerous neoplasms of the uterus, are symptomatic in up to 50% of 
affected women.1-5 The primary symptom associ-
ated with uterine fibroids is heavy menstrual 
bleeding, which can lead to anemia.6-8 Women 
with uterine fibroids can also have pelvic pain 
and pressure, urinary and gastrointestinal symp-
toms, infertility, and complications of pregnan-
cy.6,9-12 Uterine fibroids and their associated symp-
toms can have a major effect on a woman’s quality 
of life, psychological and social well-being, and 
overall health,13-18 and they impose a substantial 
economic burden on women and society.16-18
The primary management option for uterine 
fibroids is surgery, and hysterectomy is the most 
common intervention.9,11 Alternatives to surgery 
include oral contraceptives, progestins, tranexamic 
acid, and a variety of interventional therapies 
(e.g., uterine-artery embolization and magnetic 
resonance–guided focused ultrasonography).9,19-21 
However, data from randomized, controlled tri-
als showing the effectiveness of these treatment 
options in women with symptomatic fibroids are 
limited.22 Injectable depot formulations of go-
nadotropin-releasing hormone (GnRH) agonists 
are also prescribed for heavy menstrual bleeding 
associated with uterine fibroids; however, such 
treatments induce long-lasting gonadal sup-
pression resulting in adverse hypoestrogenic 
effects.6,22,23 Data show that coadministration 
with progestins (e.g., leuprolide acetate with me-
droxyprogesterone acetate) may attenuate these 
effects.24 An oral option that provides long-term, 
safe, and effective management of heavy men-
strual bleeding in women with uterine fibroids 
would be a useful alternative to existing therapies.
Elagolix is an oral, nonpeptide GnRH antago-
nist that results in rapid, reversible suppression 
of gonadotropins and ovarian sex hormones in 
women.25-27 These effects occur within 24 hours 
after the initiation of treatment and can be read-
ily reversed on discontinuation of the drug, ow-
ing to its short half-life.25 Elagolix is approved 
for the management of moderate-to-severe endo-
metriosis-associated pain; when administered 
alone, it is associated with hypoestrogenic effects 
such as decreased bone mineral density and vaso-
motor symptoms that are consistent with its 
mechanism of action.27 In a phase 2b study in-
volving women with uterine fibroids, elagolix at 
a total daily dose of 600 mg with and without 
hormonal “add-back” therapy (to replace reduced 
levels of endogenous hormones) was effective in 
reducing menstrual bleeding and had a favorable 
safety profile. Add-back therapy attenuated de-
creases in bone mineral density and other hypoes-
trogenic effects, as observed in other studies.28,29
We report the results of two identical, double-
blind, randomized, placebo-controlled, 6-month 
phase 3 trials, Elaris Uterine Fibroids 1 and 2 
(UF-1 and UF-2). The objective of both trials was 
to assess the efficacy and safety of elagolix with 
add-back therapy, as compared with placebo, in 
the management of heavy menstrual bleeding as-
sociated with uterine fibroids in premenopausal 
women. We also assessed hypoestrogenic effects 
in women who received elagolix with add-back 
therapy, as compared with elagolix alone.
Me thods
Trial Design and Oversight
UF-1 was conducted at 76 sites in the United 
States (including Puerto Rico) from December 
2015 through December 2018, and UF-2 was 
conducted at 77 sites in the United States and 
Canada from February 2016 through January 
2019. UF-1 and UF-2 were registered separately, 
and therefore the results are reported individu-
ally in this article. One patient in UF-1 and three 
patients in UF-2 who underwent randomization 
were enrolled before the trial registration date on 
ClinicalTrials.gov because of administrative error.
Each trial consisted of a period of washout of 
hormonal medication (if applicable) (Table S1 in 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org), a screening 
period of 2.5 to 3.5 months, a 6-month treat-
ment period, and a 12-month follow-up period 
(or a corresponding extension study) (Fig. S1). 
Results of the 6-month treatment period are re-
ported here.
Women were randomly assigned within 10 days 
after the start of their menses by means of an 
interactive response technology system in a 2:1:1 
ratio to receive elagolix at a dose of 300 mg twice 
daily with add-back therapy (estradiol, 1 mg, and 
norethindrone acetate, 0.5 mg, once daily), el-
agolix at a dose of 300 mg twice daily alone, or 
placebo in a matched, double-blind, double-dum-
my manner. Women who received elagolix alone 
were included as a reference group to character-
ize the effects of add-back therapy.
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The trials were conducted in accordance with 
the guidelines of the International Council for 
Harmonisation and applicable regulations and 
ethical principles of the Declaration of Helsinki. 
The study protocols were approved by the Schul-
man Institutional Review Board for central sites 
and by an institutional review board, ethics com-
mittee, or both for all other trial sites. All the 
women provided written informed consent. The 
trial sponsor, AbbVie, designed the trials and 
held and analyzed the data; the investigators 
and the sponsor jointly conducted the trials and 
gathered and interpreted the data. All the au-
thors had full access to the data, signed confi-
dentiality agreements with the sponsor regard-
ing the data, and vouch for the completeness 
and accuracy of the data and analyses and for 
the fidelity of the trial to the protocol, available 
at NEJM.org. The first draft of the manuscript 
was written by medical writers employed by the 
sponsor, with input from all the authors. All the 
authors critically reviewed and provided feedback 
on all subsequent versions of the manuscript and, 
along with the sponsor, made the decision to 
submit the manuscript for publication.
Patients
Eligible participants were premenopausal wom-
en who were between the ages of 18 and 51 years 
at the time of screening and who had an ultra-
sonography-confirmed diagnosis of uterine fi-
broids and heavy menstrual bleeding, as defined 
by more than 80 ml of menstrual blood loss per 
menstrual cycle for at least two separate cycles. 
Menstrual blood loss was measured by the alka-
line hematin method, which objectively quanti-
fied the amount of blood in sanitary products 
collected (Supplemental Methods section 1D in 
the Supplementary Appendix).30 Women were 
excluded if they were pregnant or if they had a 
persistent or complex ovarian cyst, cancer, pelvic 
inflammatory disease, a history of osteoporosis, 
or a bone mineral density T score of −1.5 or less 
at the lumbar spine, total hip, or femoral neck.
Assessments and End Points
All bleeding end points were assessed by means 
of the alkaline hematin method during the screen-
ing and treatment periods. If a woman did not 
return any used sanitary products at any visit 
during the treatment period, she was asked a 
standardized question to determine whether she 
had had any bleeding or spotting since her last 
trial visit. If no bleeding was reported over an in-
terval, the menstrual blood loss over the interval 
was counted as zero. Safety evaluations included 
the assessment of adverse events, bone mineral 
density, lipid and liver profiles, endometrial thick-
ness and biopsy results, ovarian cysts, and preg-
nancy (Supplemental Methods section 1E).
The primary end point was menstrual blood 
loss of less than 80 ml during the final month 
and at least a 50% reduction in menstrual blood 
loss from baseline to the final month. Women 
who met these two criteria but who had prema-
turely discontinued elagolix or placebo owing to 
adverse events or lack of efficacy or who had 
undergone surgery or invasive intervention for 
uterine fibroids during the trial were categorized 
as not having met the criteria for the primary 
end point.
Ranked secondary end points in hierarchical 
order were the following: the change from base-
line in menstrual blood loss at the final month; 
the percentage of women who had suppression 
of bleeding (not accounting for spotting) at the 
final month; the change from baseline in men-
strual blood loss at 6 months; the change from 
baseline in menstrual blood loss at 3 months; 
the percentage of women with a baseline hemo-
globin level of 10.5 g per deciliter or less who 
had an increase in the hemoglobin level of more 
than 2 g per deciliter at 6 months; and the 
change from baseline in menstrual blood loss at 
1 month. Other prespecified efficacy end points 
are listed in Table S2. Women were also asked to 
report their symptoms over the previous 4 weeks 
on the Uterine Fibroid Symptom and Quality of 
Life (UFS-QOL) questionnaire. This questionnaire 
includes a symptom severity score (scores range 
from 0 to 100, with higher scores indicating 
increased severity) and a health-related quality-
of-life total score that is the sum of scores on six 
subscales (concern, activities, energy and mood, 
control, self-consciousness, and sexual func-
tion). Scores on the health-related quality-of-life 
portion of the questionnaire range from 0 to 
100, with higher scores indicating a better qual-
ity of life.31
Statistical Analysis
For each trial, we calculated that a sample of 
approximately 400 women would provide at least 
90% power with a 0.05 two-sided significance 
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level to detect a difference between the group of 
women who received elagolix with add-back 
therapy and the placebo group in the primary 
end point, assuming response rates of 60% 
among the women who received elagolix with 
add-back therapy and 30% in the placebo group, 
based on results from a previous phase 2b study 
of elagolix.32 Efficacy and safety analyses were 
performed in all the women who underwent 
randomization and received at least one dose of 
elagolix or placebo, including those who prema-
turely discontinued elagolix or placebo or with-
drew consent. We performed primary efficacy 
comparisons between the group of women who 
received elagolix with add-back therapy and the 
placebo group; we did not perform efficacy com-
parisons between the group of women who re-
ceived elagolix with add-back therapy and those 
who received elagolix alone. Comparisons be-
tween the two elagolix groups were limited to 
evaluating changes in bone mineral density.
All statistical tests were performed with the 
use of SAS software (version 9.4), with a 0.05 
two-sided significance level and 95% confidence 
interval. The baseline value for menstrual blood 
loss was defined as the mean of the total men-
strual blood loss from all used sanitary products 
returned during all qualified menstrual cycles 
before or on trial day 1. Baseline for all other 
variables was defined as the last nonmissing 
measurement obtained before or on trial day 1, 
unless otherwise specified. For all women who 
underwent randomization and received treat-
ment, the final month was defined as the last 28 
days before and including the last treatment 
period visit date (if data on menstrual blood loss 
[measured with the use of the alkaline hematin 
method] that could be evaluated were available 
between the last treatment period visit date and 
the last dose date, then the last dose date was 
used). Missing data on menstrual blood loss in 
the final month were imputed with the use of 
multiple imputation (Supplemental Methods sec-
tion 1F).
The primary end point was analyzed with the 
use of a logistic-regression model with treat-
ment as the main effect and baseline menstrual 
blood loss as a covariate. For ranked secondary 
end points, the change in menstrual blood loss 
from baseline to the final month was based on 
data from multiple imputation for the primary 
efficacy analysis and analyzed with the use of a 
one-way analysis of covariance model with treat-
ment as the main effect and baseline menstrual 
blood loss as a covariate. Changes in observed 
menstrual blood loss from baseline to 1, 3, and 
6 months were analyzed with the use of a mixed 
model for repeated measures, with the fixed 
categorical effects of treatment, month, and 
treatment-by-month interaction and the continu-
ous fixed covariate of baseline menstrual blood 
loss. The percentage of women who had sup-
pression of bleeding at the final month and the 
percentage of women with a baseline hemoglo-
bin level of 10.5 g per deciliter or less who had 
an increase in the hemoglobin level of more 
than 2 g per deciliter at 6 months were each 
analyzed with the use of a Pearson’s chi-square 
test or Fisher’s exact test (if ≥20% of the cells in 
the categorical table had expected counts of <5). 
The change from baseline to 6 months in the 
variables of the UFS-QOL questionnaire was 
analyzed with the use of an analysis of covari-
ance model, with treatment as the main effect 
and baseline value as a covariate. Other results, 
including results of the sensitivity analyses for 
the primary end point and safety analyses, are 
provided in Supplemental Methods sections 1F 
and 1G.
R esult s
Patients
A total of 413 women in UF-1 and 378 in UF-2 
underwent randomization; all but 1 woman in 
UF-1 received elagolix or placebo and were in-
cluded in the efficacy and safety analyses. Of the 
women who underwent randomization and re-
ceived elagolix or placebo, 328 in UF-1 (79.6%) 
and 289 in UF-2 (76.5%) completed the 6-month 
treatment period. Similar percentages of women 
prematurely discontinued treatment across all 
trial groups (Fig. S1). Table 1 summarizes the 
baseline characteristics of the patients.
Primary Efficacy End Point
In the primary efficacy analysis with multiple 
imputation for missing data, significantly great-
er percentages of women who received elagolix 
with add-back therapy (68.5% of 206 women in 
UF-1 and 76.5% of 189 women in UF-2) met the 
criteria for the primary end point, as compared 
with women who received placebo (8.7% of 102 
women in UF-1 and 10% of 94 women in UF-2) 
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Characteristic Elaris UF-1 Elaris UF-2
Placebo 
(N = 102)
Elagolix Alone 
(N = 104)
Elagolix with 
Add-Back 
Therapy 
(N = 206)
Placebo 
(N = 94)
Elagolix Alone 
(N = 95)
Elagolix with 
Add-Back 
Therapy 
(N = 189)
Age — yr 41.6±5.7 42.6±5.2 42.6±5.3 42.5±5.4 42.2±5.4 42.5±5.3
Race — no./total no. (%)†
Black 70/102 (68.6) 69/103 (67.0) 141/206 (68.4) 63/94 (67) 66/95 (69) 124/188 (66.0)
White 30/102 (29.4) 27/103 (26.2) 59/206 (28.6) 30/94 (32) 27/95 (28) 59/188 (31.4)
Other 2/102 (2.0) 7/103 (6.8) 6/206 (3.0) 1/94 (1) 2/95 (2) 5/188 (2.7)
Missing data 0 1 0 0 0 1
Body-mass index‡ 33.8±7.7 33.4±7.7 33.3±6.8§ 33.8±7.2 34.5±7.9 33.2±6.9
Menstrual blood loss/menstrual 
cycle — ml
255.3±174.0 248.9±169.6 238.0±150.1 254.3±178.5 224.9±146.2 228.5±148.8
Hemoglobin level — g/dl 11.0±1.4 10.6±1.5 11.1±1.5 11.0±1.6 11.0±1.6 11.1±1.5
Uterine volume — cm3
Measured with TAU or TVU 478.1±356.9 499.6±437.9 474.9±388.2 549.6± 452.1 537.3±521.9 496.1±381.6
Measured with MRI¶ 561.9±437.2 617.0±582.3 508.6±342.2 798.6±730.9 675.7±906.2 676.8±559.1
Average fibroid volume — cm3
Measured with TAU or TVU‖ 52.1±72.2 44.2±64.2 52.0±69.7 73.3±100.4 67.4±132.3 57.3±104.8
Measured with MRI** 73.1±98.1 60.2±70.3 66.0±73.7 104.3±120.5 83.3±130.8 72.0±68.2
UFS-QOL score††
Symptom severity score‡‡ 61.7±19.2 60.4±22.5 57.3±22.2 60.5±23.4 63.7±20.4 60.9±21.6
Health-related quality-of-life 
total score§§
40.7±20.3 42.5±23.3 44.1±23.5 43.0±22.8 42.2±24.0 43.3±24.2
Bone mineral density z score
Lumbar spine 0.9±1.0 1.1±1.2 1.0±1.0§ 1.1±1.1 0.9±1.2 1.1±1.2
Total hip 0.7±0.9 0.8±0.9 0.8±0.9§ 0.7±1.0 0.8±1.0 0.8±0.9
Femoral neck 0.5±0.8 0.6±0.9 0.6±0.9§ 0.6±0.9 0.6±0.9 0.6±0.9
*  Plus–minus values are means ±SD. MRI denotes magnetic resonance imaging, TAU transabdominal ultrasonography, and TVU transvagi-
nal ultrasonography.
†  Race was reported by the women.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  Data shown are for 205 patients.
¶  For the Elaris UF-1 trial, data shown are for 48 patients who received placebo, 51 patients who received elagolix alone, and 96 patients 
who received elagolix with add-back therapy. For the Elaris UF-2 trial, data shown are for 51 patients who received placebo, 52 patients 
who received elagolix alone, and 89 patients who received elagolix with add-back therapy.
‖  For the Elaris UF-1 trial, data shown are for 100 patients who received placebo, 102 patients who received elagolix alone, and 203 patients 
who received elagolix with add-back therapy. For the Elaris UF-2 trial, data shown are for 92 patients who received placebo, 95 patients 
who received elagolix alone, and 186 patients who received elagolix with add-back therapy.
**  For the Elaris UF-1 trial, data shown are for 47 patients who received placebo, 45 patients who received elagolix alone, and 83 patients 
who received elagolix with add-back therapy. For the Elaris UF-2 trial, data shown are for 45 patients who received placebo, 52 patients 
who received elagolix alone, and 92 patients who received elagolix with add-back therapy.
††  On the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire, scores for symptom severity range from 0 to 100, with 
higher scores indicating increased severity. Total scores for health-related quality of life range from 0 to 100, with higher scores indicating 
a better quality of life.
‡‡  For the Elaris UF-1 trial, data shown are for 102 patients who received placebo, 103 patients who received elagolix alone, and 206 patients 
who received elagolix with add-back therapy. For the Elaris UF-2 trial, data shown are for 92 patients who received placebo, 94 patients 
who received elagolix alone, and 186 patients who received elagolix with add-back therapy.
§§  For the Elaris UF-1 trial, data shown are for 102 patients who received placebo, 103 patients who received elagolix alone, and 206 patients 
who received elagolix with add-back therapy. For the Elaris UF-2 trial, data shown are for 90 patients who received placebo, 94 patients 
who received elagolix alone, and 185 patients who received elagolix with add-back therapy.
Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*
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(P<0.001 for the two trials) (Fig. 1). Among women 
who received elagolix alone, 84.1% of 104 women 
in UF-1 and 77% of 95 women in UF-2 met the 
criteria for the primary end point. Results of all 
sensitivity analyses of the primary end point were 
similar to those of the primary analysis (Table S3).
Ranked Secondary and Other Efficacy  
End Points
Elagolix with add-back therapy, as compared with 
placebo, resulted in significant improvements in 
the prespecified ranked secondary outcomes: a 
greater reduction in menstrual blood loss from 
baseline to the final month, a higher percentage 
of women with suppression of bleeding at the fi-
nal month, a greater reduction in menstrual blood 
loss from baseline to 6 months and 3 months, a 
higher percentage of women with a baseline 
hemoglobin level of 10.5 g per deciliter or less 
who had an increase in the hemoglobin level of 
more than 2 g per deciliter at 6 months, and a 
greater reduction in menstrual blood loss from 
baseline to 1 month (Table 2). (Reductions in 
menstrual blood loss over time are shown in 
Figure S2.) In the group of women who received 
elagolix with add-back therapy, 48.1% in UF-1 
and 52.9% in UF-2 had amenorrhea (no bleeding 
or spotting) in the final month (as compared 
with 4% and 5%, respectively, in the placebo 
group); the same percentages of women also had 
control of bleeding (≤1 day of spotting) in the 
final month (Table S4). (Results of measures of 
hemoglobin, uterine volume, and average fibroid 
volume are shown in Figures S3 through S5.)
On the UFS-QOL questionnaire, scores for 
symptom severity range from 0 to 100, with 
higher scores indicating increased severity. The 
least-squares mean (±SE) change in symptom 
severity from baseline to 6 months in women 
who received elagolix with add-back therapy was 
−33.2±1.61 in UF-1 and −41.4±1.60 in UF-2 (as 
compared with −10.3±2.25 and −7.9±2.28, respec-
tively, in women who received placebo). On the 
health-related quality of life total score portion 
of the questionnaire, scores range from 0 to 100, 
with higher scores indicating a better quality of 
Figure 1. Reduction in Heavy Menstrual Bleeding in Women with Uterine Fibroids.
Shown are the percentages of women who met the criteria for the primary end point (a menstrual blood loss [MBL] 
volume of <80 ml in the final month and a ≥50% reduction in MBL volume from baseline to the final month) in the 
two trials. A significantly greater percentage of women who received elagolix with add-back therapy met the criteria 
for the primary end point than women who received placebo. The final month was defined as the last 28 days be-
fore and including the last treatment period visit date (if data on menstrual blood loss [measured with the use of 
the alkaline hematin method] that could be evaluated were available between the last treatment period visit date 
and the last dose date, then the last dose date was used). CI denotes confidence interval.
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life. The least-squares mean (±SE) change in 
women who received elagolix with add-back 
therapy was 38.0±1.62 in UF-1 and 42.0±1.62 in 
UF-2 (as compared with 10.9±2.27 and 6.5±2.32, 
respectively, in women who received placebo) 
(Fig. S6).
Safety
More than 60% of the women in each trial group 
reported at least one adverse event. The inci-
dence of any adverse event was significantly 
higher among women who received elagolix 
alone in UF-1 (P<0.001) and among those who 
received elagolix plus add-back therapy in UF-2 
(P<0.05) than among those who received placebo 
(Table 3). Most adverse events were considered 
by the investigators to be mild or moderate in 
severity. Serious and severe adverse events are 
listed in Tables S5 and S6, respectively. All seri-
ous adverse events that were reported in the el-
agolix groups were resolved by the end of the 
trial. Hot flushes were significantly more com-
mon with elagolix plus add-back therapy (20.4% 
and 19.6%, respectively, in UF-1 and UF-2) and 
elagolix alone (64.4% and 43%) than with pla-
cebo (8.8% and 4%); in UF-1 and UF-2, night 
sweats were significantly more common with 
elagolix alone (26.9% and 25%, respectively) 
than with placebo (2.9% and 5%, respectively) 
(Table 3). Details regarding the severity profiles 
of hot flushes and night sweats each month and 
for the entire treatment course are shown in 
Table S7 and Figure S7. In addition, in UF-1, 
metrorrhagia was significantly more common 
among women who received elagolix plus add-
back therapy than among those who received 
placebo (6.3% vs. 0%). No deaths were reported 
during the treatment period in either trial. Two 
pregnancies in the placebo group (one live birth 
and one spontaneous abortion) and one in the 
elagolix-alone group (an ectopic pregnancy) were 
reported during the treatment period in the two 
trials (Table S8).
There were no significant differences in the 
trials between the women who received elagolix 
with add-back therapy and those who received 
placebo with respect to the mean percent change 
in bone mineral density in the lumbar spine, total 
hip, or femoral neck from baseline to 6 months 
(Fig. 2). Although not all patients had a decrease 
in bone mineral density, the mean percent de-
crease in bone mineral density was significantly 
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smaller with elagolix plus add-back therapy than 
with elagolix alone in all locations, except the 
femoral neck in UF-2. (Categorical assessments 
of changes in bone mineral density are summa-
rized in Figure S8.)
Both elagolix groups had a mean increase 
from baseline in serum lipid levels (i.e., total 
cholesterol, low-density lipoprotein cholesterol, 
high-density lipoprotein cholesterol, and triglyc-
eride levels), relative to placebo. These increases 
generally occurred within the first 3 months 
after initiation of treatment and then stabilized 
(Fig. S9).
The mean levels of liver aminotransferases, 
alkaline phosphatase, and bilirubin from base-
line to 6 months were not significantly higher in 
the group of women who received elagolix plus 
add-back therapy than in the group of women 
who received placebo (Fig. S10). Across both tri-
als, 10 women — all in the elagolix groups (6 in 
UF-1: 3 [2.9%] in elagolix alone and 3 [1.5%] in 
elagolix with add-back therapy; 4 in UF-2: 1 [1%] 
Event Elaris UF-1 Elaris UF-2
Placebo 
 (N = 102)
Elagolix Alone 
 (N = 104)
Elagolix with 
Add-Back 
Therapy 
 (N = 206)
Placebo 
 (N = 94)
Elagolix Alone 
 (N = 95)
Elagolix with 
Add-Back 
Therapy 
 (N = 189)
number (percent)
Adverse events
Any adverse event 71 (69.6) 94 (90.4)† 140 (68.0) 59 (63) 72 (76) 143 (75.7)‡
Any serious adverse event§ 5 (4.9) 3 (2.9) 3 (1.5) 1 (1) 4 (4) 7 (3.7)
Any severe adverse event¶ 4 (3.9) 9 (8.7) 19 (9.2) 6 (6) 11 (12) 17 (9.0)
Any adverse event leading 
to trial-drug discontinu-
ation
8 (7.8) 10 (9.6) 22 (10.7) 5 (5) 12 (13) 16 (8.5)
Adverse events in ≥5% of 
women who received 
 elagolix with add-back 
therapy in either trial
Hot flushes 9 (8.8) 67 (64.4)† 42 (20.4)‖ 4 (4) 41 (43)† 37 (19.6)†
Nausea 10 (9.8) 7 (6.7) 23 (11.2) 9 (10) 4 (4) 14 (7.4)
Headache 9 (8.8) 17 (16.3) 17 (8.3) 5 (5) 13 (14) 20 (10.6)
Night sweats 3 (2.9) 28 (26.9)† 14 (6.8) 5 (5) 24 (25)† 20 (10.6)
Fatigue 2 (2.0) 1 (1.0) 14 (6.8) 5 (5) 3 (3) 10 (5.3)
Dysmenorrhea 4 (3.9) 1 (1.0) 13 (6.3) 6 (6) 0‡ 7 (3.7)
Metrorrhagia 0 1 (1.0) 13 (6.3)‖ 1 (1) 0 7 (3.7)
Nasopharyngitis 4 (3.9) 6 (5.8) 10 (4.9) 8 (9) 4 (4) 10 (5.3)
Decreased libido 0 5 (4.8) 7 (3.4) 2 (2) 3 (3) 10 (5.3)
Urinary tract infection 3 (2.9) 3 (2.9) 3 (1.5) 5 (5) 2 (2) 12 (6.3)
*  All adverse events were summarized with the use of the Medical Dictionary for Regulatory Activities, version 21.0, and are listed in descending 
order of incidence, starting with women who received elagolix with add-back therapy, then women who received elagolix alone, and then 
women who received placebo in Elaris UF-1, followed by women who received elagolix with add-back therapy, then women who received el-
agolix alone, and then women who received placebo in Elaris UF-2.
†  P<0.001 for the comparison with placebo, according to Fisher’s exact test.
‡  P<0.05 for the comparison with placebo, according to Fisher’s exact test.
§  Serious adverse events were defined as life-threatening, resulting in hospitalization or medical or surgical intervention to prevent a serious 
outcome, or resulting in persistent disability or death.
¶  The severity of each adverse event was rated by the investigators as mild, moderate, or severe.
‖  P<0.01 for the comparison with placebo, according to Fisher’s exact test.
Table 3. Adverse Events.*
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in elagolix alone and 3 [1.6%] in elagolix with 
add-back therapy) — had elevations in liver ami-
notransferases that were greater than 3 times 
the upper limit of the normal range; none of 
these women had concurrent elevations in bili-
rubin levels. All elevated aminotransferase levels 
returned to the normal range, with the decline 
seen within 1 to 4 months after peak values, 
regardless of whether the women continued to 
receive elagolix (8 women) or not (2 women).
Despite cycle-related differences, there was a 
decrease in mean endometrial thickness among 
women who received elagolix plus add-back ther-
apy at 6 months (Fig. S11). No cases of endome-
trial hyperplasia or cancer were detected on en-
dometrial biopsies in the elagolix groups; there 
was one case of hyperplasia in the placebo group 
(Table S9). No new ovarian cysts were reported 
during elagolix treatment (Table S10).
Discussion
In two identical, double-blind, randomized, pla-
cebo-controlled, 6-month phase 3 trials involv-
ing women with heavy menstrual bleeding as-
sociated with uterine fibroids, menstrual blood 
loss was significantly lower among women who 
received elagolix with add-back therapy than 
among those who received placebo. Elagolix with 
add-back therapy was associated with a signifi-
cantly greater mean reduction in menstrual blood 
loss from baseline to the final month, a higher 
percentage of women with suppression of bleed-
ing, a greater mean reduction in menstrual blood 
loss from baseline to 6 months and 3 months, a 
higher percentage of women with a low baseline 
hemoglobin level (≤10.5 g per deciliter) who had 
an increase in the hemoglobin level that was 
greater than 2 g per deciliter at 6 months, and a 
greater mean reduction in menstrual blood loss 
from baseline to 1 month. Findings with respect 
to uterine volume (measured by means of mag-
netic resonance imaging) and improvements in 
quality of life were consistent with the effects on 
the primary and secondary end points.
Elagolix was associated with a low incidence 
of serious adverse events; none of these events 
were related to drug-induced liver injury, and 
there were no clinically meaningful endometrial 
abnormalities. Elagolix with add-back therapy at-
tenuated decreases in bone mineral density seen 
with elagolix alone. In both trials, the mean per-
cent changes in bone mineral density in all 
measured sites did not significantly differ be-
tween the groups of women who received elago-
lix with add-back therapy and those who re-
ceived placebo. The decreases from baseline in 
bone mineral density that occurred in women who 
received elagolix alone were significantly greater 
than in those who received elagolix with add-
back therapy and also significantly greater than 
in those who received placebo (except at the 
femoral neck in UF-2). The attenuation of hy-
poestrogenic effects in women who received el-
agolix plus add-back therapy as compared with 
those who received elagolix alone is consistent 
with the results of other trials of GnRH ana-
logues.28,29 Because of the mechanism of action, 
hot flushes still occurred in a higher percentage 
of women who received elagolix with add-back 
therapy than in those who received placebo.
These large prospective trials involving women 
with uterine fibroids included a high percentage 
of black women, who are at higher risk for uterine 
fibroids and tend to have more severe symptoms 
than white women. The alkaline hematin method 
was used to quantify all bleeding end points.3-5,33-39 
The present data inform the efficacy and safety 
of this treatment through 6 months; the 6-month 
extension trial (up to 12 months of treatment) 
was conducted to provide more information on 
longer-term benefits and risks of elagolix with 
add-back therapy, as was previously shown in 
extension studies of elagolix in women with en-
dometriosis-associated pain.40 Since the trials 
were designed primarily to compare elagolix plus 
add-back therapy with placebo and prespecified a 
comparison of the two elagolix groups only with 
respect to bone mineral density, we cannot make 
conclusions regarding elagolix with add-back ther-
apy as compared with elagolix alone with respect 
to the effects on other outcomes.
In both trials reported here, the risk of heavy 
menstrual bleeding among premenopausal wom-
en with uterine fibroids was significantly lower 
among women who received elagolix, an oral 
GnRH antagonist, at a dose of 300 mg twice daily 
with add-back therapy for 6 months than among 
those who received placebo. As compared with 
elagolix alone, add-back therapy attenuated de-
creases in bone mineral density associated with 
elagolix alone.
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